Síndromes hipereosinofílicosmastocitosis sistémica
- Salido Fiérrez, E.
- Cabañas Perianes, Valentín
- Rubio Tejero, Antonio Ignacio
- Moraleda Jiménez, José María
ISSN: 0304-5412
Argitalpen urtea: 2012
Zenbakien izenburua: Enfermedades de la sangre (II): enfermedades de los leucocitos
Saila: 11
Zenbakia: 21
Orrialdeak: 1298-1308
Mota: Artikulua
Beste argitalpen batzuk: Medicine: Programa de Formación Médica Continuada Acreditado
Laburpena
Eosinophilia may be a reactive phenomenon mediated by cytokines (secondary) or may be a component of phenotype of an underlying hematologic malignancy (primary). Primary eosinophilia is classified as an idiopathic clonal disease depending on the presence or absence of certain molecular, cytogenetic or histological findings. Hypereosinophilic syndrome (HES) encompass a spectrum of clonal (primary SHE) or idiopathic (idiopathic SHE) diseases that have increased eosinophils in peripheral blood and tissue damage. Mast cell disease, or mastocytosis, includes a variety of disorders that are characterized by clonal proliferations of mast cells in one or multiple organs. The mastocytosis range from indolent and isolated proliferations to aggressive and systemic disorders. Mastocytosis is included in the myeloproliferative neoplasms category in the 2008 World Health Organization (WHO) classification. This chapter describes both disorders, recent classifications, clinical manifestations, systematic diagnosis and current treatments.